Journal article
Attitudes towards antenatal vaccination, Group B streptococcus and participation in clinical trials: Insights from focus groups and interviews of parents and healthcare professionals
- Abstract:
- Introduction Antenatal vaccination has become a part of routine care during pregnancy in the UK and worldwide, leading to improvements in health for both pregnant women and their infants. However, uptake remains sub-optimal. Other antenatal vaccines targeting major neonatal pathogens, such as Group B streptococcus (GBS), the commonest cause of sepsis and meningitis in the neonatal period, are undergoing clinical trials but more information is needed on how to improve acceptance of such vaccines. Methods Qualitative study using focus groups and interviews; involving 14 pregnant women, 8 mothers with experience of GBS, and 28 maternity healthcare professionals. Questions were asked regarding antenatal vaccines, knowledge of GBS, attitudes to a potential future GBS vaccine and participation in antenatal vaccine trials. Results All participants were very cautious about vaccination during pregnancy, with harm to the baby being a major concern. Despite this, the pregnant women and parents with experience of GBS were open to the idea of an antenatal GBS vaccine and participating in research, while the maternity professionals were less positive. Major barriers identified included lack of knowledge about GBS and the reluctance of maternity professionals to be involved. Interpretation In order for a future GBS vaccine to be acceptable to both pregnant women and the healthcare professionals advising them, a major awareness campaign would be required with significant focus on convincing and training maternity professionals.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
- 
                - 
                        
                        (Preview, Accepted manuscript, pdf, 110.5KB, Terms of use)
 
- 
                        
                        
- Publisher copy:
- 10.1016/j.vaccine.2016.06.024
Authors
      
      + National Institute for Health Research Oxford Biomedical Research Centre
      
    More from this funder
    	
      
  
            - Funding agency for:
- Locock, L
- Publisher:
- Elsevier
- Journal:
- Vaccine More from this journal
- Volume:
- 34
- Issue:
- 34
- Pages:
- 4056–4061
- Publication date:
- 2016-06-16
- Acceptance date:
- 2016-06-03
- DOI:
- EISSN:
- 
                    1873-2518
- ISSN:
- 
                    0264-410X
- Keywords:
- Pubs id:
- 
                  pubs:625749
- UUID:
- 
                  uuid:69ed1585-94ee-413c-8e95-4a3d63a0da16
- Local pid:
- 
                    pubs:625749
- Source identifiers:
- 
                  625749
- Deposit date:
- 
                    2016-06-07
Terms of use
- Copyright holder:
- Elsevier Ltd
- Copyright date:
- 2016
- Notes:
- Copyright © 2016 Elsevier Ltd. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.vaccine.2016.06.024
If you are the owner of this record, you can report an update to it here: Report update to this record